Cornea Associates of Texas   Report issue

Academic/Hospital Phase 1
Founded: Dallas TX United States

Organization Overview

First Clinical Trial
2019
NCT04177082
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cornea Associates of Texas

Active Ingredients

Drugs in Phase 1 Trials (1)

riboflavin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Corneal Dystrophies, Hereditary (Phase 1)

Keratoconus (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1